8/12/2013

The European Commission approved Johnson & Johnson's Velcade, or bortezomib, in combination with dexamethasone and thalidomide, as induction treatment for treatment-naive multiple myeloma patients who are candidates for stem cell transplant and high-dose chemotherapy. The approval strengthens Velcade's position in the multiple myeloma market.

Full Story:
PharmaTimes (U.K.)

Related Summaries